Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

Area of Science:

• Neurology
• Pharmacology
• Immunology

Background:

• The treatment landscape for multiple sclerosis (MS) is rapidly evolving.
• New oral pharmacologic agents and improved diagnostic tools for JC virus exposure are key drivers of change.
• Several new MS therapies are nearing market approval, expanding treatment options.

Purpose of the Study:

• To summarize clinical trial data on the efficacy and safety of oral agents for MS.
• To discuss the impact of new therapies and diagnostic advancements on the MS treatment paradigm.
• To provide an overview of the current and future therapeutic strategies for multiple sclerosis.

Main Methods:

• Review of clinical trial results for oral multiple sclerosis therapies.
• Analysis of the impact of JC virus antibody testing on treatment decisions.
• Discussion of safety and tolerability profiles of emerging and established MS medications.

Main Results:

• Teriflunomide and BG-12 are anticipated for FDA approval in 2012-2013 for relapsing MS.
• Fingolimod is widely used as a first-line or alternative therapy due to its oral administration.
• JC virus antibody testing enables broader use of natalizumab as a first-line treatment for JC virus-negative patients.

Conclusions:

• The therapeutic environment for multiple sclerosis is undergoing significant transformation.
• New oral agents offer improved efficacy, safety, and tolerability profiles.
• The integration of new drugs and diagnostic tools is reshaping MS management strategies.